Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To estimate the progression-free survival (PFS) failure rate | Maximum 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| To enhance the knowledge on known undesirable effects under routine conditions and to obtain further knowledge about so far unknown and rare undesired effects | Every 3 months (during 3 years) | |
| To prescribe the change in patient's quality of life (QoL) during therapy. |
Not provided
Inclusion Criteria:
- Patients with advanced hormone-dependent prostate carcinoma that are eligible for hormone therapy
Exclusion Criteria:
- Patients with a contraindication for prescription of Firmagon®
Not provided
Not provided
Not provided
Not provided
Patients with advanced prostate cancer
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Development Support | Ferring Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jeroen Bosch Ziekenhuis, locatie Carolus | 's-Hertogenbosch | Netherlands | ||||
| Flevoziekenhuis |
Not provided
Not provided
Not provided
Not provided
| From study start and after 6 months |
| To assess the improvement of IPSS from baseline after 3 months of Firmagon therapy and at end-of-therapy | From study start, after 3 months and at end of treatment |
| To assess the reduction of prostate volume (neoadjuvant therapy) | Fom baseline after 3 months |
| Almere Stad |
| Netherlands |
| Bovenij Ziekenhuis | Amsterdam | Netherlands |
| Wilhelminaziekenhuis | Assen | Netherlands |
| Rode Kruis Ziekenhuis | Beverwijk | Netherlands |
| Tergooiziekenhuizen | Blaricum | Netherlands |
| Amphia Ziekenhuis | Breda | Netherlands |
| Ljsselland Ziekenhuis | Capelle aan den IJssel | Netherlands |
| Reinier de Graaf Groep | Delft | Netherlands |
| Deventer Ziekenhuis | Deventer | Netherlands |
| Slingeland Ziekenhuis | Doetinchem | Netherlands |
| Alb.Schweitzer Ziekenhuis, loc. Dordwijk | Dordrecht | Netherlands |
| Gelderse Vallei, loc. Barneveld | Ede | Netherlands |
| Admiraal de Ruyter Ziekenhuis | Flushing | Netherlands |
| St. Anna Ziekenhuis | Geldrop | Netherlands |
| Admiraal de Ruyter Ziekenhuis | Goes | Netherlands |
| Rivas Beatrixziekenhuis | Gorinchem | Netherlands |
| Het Groene Hart Ziekenhuis | Gouda | Netherlands |
| Buitenpolikliniek | Groenlo | Netherlands |
| Martini Ziekenhuis | Groningen | Netherlands |
| Ziekenhuis St Jansdal | Harderwijk | Netherlands |
| Elkerliek Ziekenhuis | Helmond | Netherlands |
| Tergooiziekenhuizen | Hilversum | Netherlands |
| Medisch Centrum Leeuwarden | Leeuwarden | Netherlands |
| LUMC | Leiden | Netherlands |
| Rijnland Ziekenhuis | Leiderdorp | Netherlands |
| MUMC | Maastricht | Netherlands |
| Ziekenhuis Bernhoven, loc. Oss | Oss | Netherlands |
| Waterland Ziekenhuis | Purmerend | Netherlands |
| Franciscus Ziekenhuis | Roosendaal | Netherlands |
| Havenziekenhuis | Rotterdam | Netherlands |
| Vlietland Ziekenhuis | Rotterdam | Netherlands |
| Orbis Medisch Centrum | Sittard-Geleen | Netherlands |
| Alb. Schweitzer Ziekenhuis loc. Sliedrecht | Sliedrecht | Netherlands |
| Antonius Ziekenhuis | Sneek | Netherlands |
| Ruwaard v Putten/vWeel Bethesda Zkhs | Spijkenisse | Netherlands |
| Zorgzaam Ziekenhuis | Terneuzen | Netherlands |
| Hagaziekenhuis loc. Leyweg | The Hague | Netherlands |
| Hagaziekenhuis loc. Sportlaan | The Hague | Netherlands |
| Ziekenhuis Rivierenland | Tiel | Netherlands |
| Antonius Ziekenhuis, loc. Oudenrijn | Utrecht | Netherlands |
| Diakonessenhuis Utrecht | Utrecht | Netherlands |
| Ziekenhuis Bernhoven, loc. Veghel | Veghel | Netherlands |
| Maxima Medisch Centrum | Veldhoven | Netherlands |
| St. Jans Gasthuis | Weert | Netherlands |
| Albert Schweitzer Ziekenhuis | Zwijndrecht | Netherlands |
| Isala Klinieken | Zwolle | Netherlands |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided